GSK Advances mRNA Influenza Vaccine Into Phase III Trials

GSK advances its mRNA influenza vaccine into Phase III clinical trials, positioning to challenge Moderna's dominance in the mRNA vaccine market following the FDA's approval of mFLUSIVA in August 2026.